The Federal Circuit has provided additional guidance about an appellant’s standing to appeal IPR decisions after settling the related litigations and entering into patent license agreements. In its second decision between the parties on this topic, the court has dismissed
Continue Reading Appealing IPR Decisions – Art. III Standing in the Context of Litigation Settlements and Licenses
Earlier this month, in University of Strathclyde v. Clear-Vu Lighting LLC, the Court of Appeals for the Federal Circuit (“the CAFC”) reversed a decision by the Patent Trial and Appeal Board (“the Board”) that found claims 1-4 of the University
Continue Reading Federal Circuit Reaffirms Obviousness Standard by Reversing PTAB in University of Strathclyde v. Clear-Vu Lighting
Introduction
Universities and certain colleges in the United States (US) spend billions of dollars on research and development (R&D) each year to advance knowledge across the gamut of Arts, Humanities, and Science, Technology, Engineering, and Mathematics (STEM) fields. That R&D
Continue Reading Three (3) Initial Considerations for Entrepreneurial Faculty, Researchers, Post-Docs, and Graduate Students
Updated November 15, 2021
Google’s parent company Alphabet announced the launch of a new company this week dedicated to applying deep learning methods to drug discovery.
The new company is called Isomorphic Laboratories and will be led by Demis Hassabis, also the CEO of DeepMind,
Continue Reading Alphabet Dives Further Into AI-Driven Drug Discovery
On October 26, 2021, the Patent Trial and Appeal Board (PTAB) granted Regeneron’s petition to institute an inter partes review (IPR) of Novartis’s patent U.S. Pat. No. 9,220,631 (“the ’631 patent”), which covers a pre-filled glass syringe for injecting a
Continue Reading PTAB Agrees to Review Novartis’ Patent for an Ophthalmic Injection Syringe
Vertex Pharmaceuticals and Mammoth Biosciences, a Brisbane, California-based genetic research company, announced a new collaboration for the development of in vivo gene therapies for rare diseases using Mammoth’s ultra-small CRISPR systems.
Over the past couple of years, Mammoth Biosciences, the
Continue Reading Vertex and Mammoth Biosciences Ink $700M Deal for Ultra-Small CRISPR Systems
The U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB) recently released an updated Orange Book patent/biologic patent study on August 11, 2021. This is the third report providing data on post-grant petitions filed against Orange Book and
Continue Reading Key Trends in PTAB’s 2021 Orange Book and Biologic Patent Study
This is a second-part of an article regarding U.S. Trademark Opposition strategies.
U.S. trademark opposition proceedings need not be expensive or protracted. This is one of the surprising conclusions for global trademark owners who seek to protect their rights in
Continue Reading U.S. Trademark Opposition Guide
On October 15, 2021, the U.S. Food and Drug Administration (“FDA”) approved Boehringer Ingelheim’s Cyltezo® (adalimumab-adbm), the first interchangeable biosimilar to AbbVie’s blockbuster immunosuppressant Humira® (adalimumab). We previously discussed Boehringer Ingelheim’s Citizen Petition requesting a change in the FDA’s interpretation
Continue Reading Takeaways from FDA’s Approval of the First Interchangeable Biosimilar for Humira®
